Gautvik, Kaare M.
Olstad, Ole K.
Raue, Ulrika
Gautvik, Vigdis T.
Kvernevik, Karl J.
Utheim, Tor P.
Ravnum, Solveig
Kirkegaard, Camilla
Wiig, Håvard
Jones, Garan
Pilling, Luke C.
Trappe, Scott
Raastad, Truls
Reppe, Sjur http://orcid.org/0000-0002-4330-5379
Funding for this research was provided by:
Helse Sør-Øst RHF (52009/8029)
Sixth Framework Programme (LSHM-CT-2003-502941)
Lovisenberg Diakonale Sykehus
Foundation for the National Institutes of Health (AG15833, AG00831, AG18409)
Eli Lilly and Company
Article History
Received: 14 January 2022
Accepted: 19 September 2022
First Online: 1 October 2022
Declarations
:
: All participants provided written informed consent. The study was approved by the Norwegian Regional Ethical Committee (REK no: 2010/2539) and was conducted according to the Declaration of Helsinki.
: Not applicable.
: The authors declare that they have no competing interests.